NCT07082270View on ClinicalTrials.gov

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2028

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Carfilzomib

Given IV

PROCEDURE

Computed Tomography

Undergo PET/CT and/or CT

DRUG

Daratumumab and Recombinant Human Hyaluronidase

Given SC

DRUG

Dexamethasone

Given PO

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Selvigaltin

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER